A citation-based method for searching scientific literature

Chiara Ricci, Massimiliano Ruscica, Marina Camera, Laura Rossetti, Chiara Macchi, Alessandra Colciago, Ilaria Zanotti, Maria Giovanna Lupo, Maria Pia Adorni, Arrigo F G Cicero, Federica Fogacci, Alberto Corsini, Nicola Ferri. Sci Rep 2018
Times Cited: 98







List of co-cited articles
1082 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
39

New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway.
Zhi-Han Tang, Juan Peng, Zhong Ren, Jing Yang, Ting-Ting Li, Tao-Hua Li, Zuo Wang, Dang-Heng Wei, Lu-Shan Liu, Xi-Long Zheng,[...]. Atherosclerosis 2017
105
32

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Marianne Abifadel, Mathilde Varret, Jean-Pierre Rabès, Delphine Allard, Khadija Ouguerram, Martine Devillers, Corinne Cruaud, Suzanne Benjannet, Louise Wickham, Danièle Erlich,[...]. Nat Genet 2003
31

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
Nicola Ferri, Gianpaolo Tibolla, Angela Pirillo, Francesco Cipollone, Andrea Mezzetti, Stefano Pacia, Alberto Corsini, Alberico Luigi Catapano. Atherosclerosis 2012
160
30

Local effects of human PCSK9 on the atherosclerotic lesion.
Ilaria Giunzioni, Hagai Tavori, Roman Covarrubias, Amy S Major, Lei Ding, Youmin Zhang, Rachel M DeVay, Liang Hong, Daping Fan, Irene M Predazzi,[...]. J Pathol 2016
100
30

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.
Nabil G Seidah, Suzanne Benjannet, Louise Wickham, Jadwiga Marcinkiewicz, Stephanie Belanger Jasmin, Stefano Stifani, Ajoy Basak, Annik Prat, Michel Chretien. Proc Natl Acad Sci U S A 2003
805
29

PCSK9 is a critical regulator of the innate immune response and septic shock outcome.
Keith R Walley, Katherine R Thain, James A Russell, Muredach P Reilly, Nuala J Meyer, Jane F Ferguson, Jason D Christie, Taka-aki Nakada, Chris D Fjell, Simone A Thair,[...]. Sci Transl Med 2014
211
28

Cross-talk between LOX-1 and PCSK9 in vascular tissues.
Zufeng Ding, Shijie Liu, Xianwei Wang, Xiaoyan Deng, Yubo Fan, Jiwani Shahanawaz, Robert J Shmookler Reis, Kattayi I Varughese, Tatsuya Sawamura, Jawahar L Mehta. Cardiovasc Res 2015
128
27

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
Jonathan C Cohen, Eric Boerwinkle, Thomas H Mosley, Helen H Hobbs. N Engl J Med 2006
26

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
24

Inflammation stimulates the expression of PCSK9.
Kenneth R Feingold, Arthur H Moser, Judy K Shigenaga, Sophie M Patzek, Carl Grunfeld. Biochem Biophys Res Commun 2008
152
23

Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta.
Zufeng Ding, Shijie Liu, Xianwei Wang, Xiaoyan Deng, Yubo Fan, Changqing Sun, Yannian Wang, Jawahar L Mehta. Antioxid Redox Signal 2015
101
23

Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.
Massimiliano Ruscica, Chiara Ricci, Chiara Macchi, Paolo Magni, Riccardo Cristofani, Jingwen Liu, Alberto Corsini, Nicola Ferri. J Biol Chem 2016
72
30

PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement.
Nicola Ferri, Silvia Marchianò, Gianpaolo Tibolla, Roberta Baetta, Ashish Dhyani, Massimiliano Ruscica, Patrizia Uboldi, Alberico L Catapano, Alberto Corsini. Atherosclerosis 2016
58
37

Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.
Massimiliano Ruscica, Nicola Ferri, Federica Fogacci, Martina Rosticci, Margherita Botta, Silvia Marchiano, Paolo Magni, Sergio D'Addato, Marina Giovannini, Claudio Borghi,[...]. J Am Heart Assoc 2017
53
37

Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis.
Dhruva J Dwivedi, Peter M Grin, Momina Khan, Annik Prat, Ji Zhou, Alison E Fox-Robichaud, Nabil G Seidah, Patricia C Liaw. Shock 2016
71
26

PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study.
Jin M Cheng, Rohit M Oemrawsingh, Hector M Garcia-Garcia, Eric Boersma, Robert-Jan van Geuns, Patrick W Serruys, Isabella Kardys, K Martijn Akkerhuis. Atherosclerosis 2016
92
20

PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages.
Zhihan Tang, Lu Jiang, Juan Peng, Zhong Ren, Dangheng Wei, Chunyang Wu, Lihong Pan, Zhisheng Jiang, Lushan Liu. Int J Mol Med 2012
118
18

Genetic and metabolic determinants of plasma PCSK9 levels.
Susan G Lakoski, Thomas A Lagace, Jonathan C Cohen, Jay D Horton, Helen H Hobbs. J Clin Endocrinol Metab 2009
349
17

PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia.
Sophie J Bernelot Moens, Annette E Neele, Jeffrey Kroon, Fleur M van der Valk, Jan Van den Bossche, Marten A Hoeksema, Renate M Hoogeveen, Johan G Schnitzler, Marie T Baccara-Dinet, Garen Manvelian,[...]. Eur Heart J 2017
96
16

PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages.
Zufeng Ding, Shijie Liu, Xianwei Wang, Sue Theus, Xiaoyan Deng, Yubo Fan, Sichang Zhou, Jawahar L Mehta. Cardiovasc Res 2018
43
37

PCSK9 as a Positive Modulator of Platelet Activation.
Marina Camera, Laura Rossetti, Silvia S Barbieri, Ilaria Zanotti, Barbara Canciani, Daniela Trabattoni, Massimiliano Ruscica, Elena Tremoli, Nicola Ferri. J Am Coll Cardiol 2018
34
44

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.
Susan Kühnast, José W A van der Hoorn, Elsbet J Pieterman, Anita M van den Hoek, William J Sasiela, Viktoria Gusarova, Anusch Peyman, Hans-Ludwig Schäfer, Uwe Schwahn, J Wouter Jukema,[...]. J Lipid Res 2014
126
15

Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages.
Maria Pia Adorni, Eleonora Cipollari, Elda Favari, Ilaria Zanotti, Francesca Zimetti, Alberto Corsini, Chiara Ricci, Franco Bernini, Nicola Ferri. Atherosclerosis 2017
65
23

Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis.
John H Boyd, Christopher D Fjell, James A Russell, Demetrios Sirounis, Mihai S Cirstea, Keith R Walley. J Innate Immun 2016
66
22

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
Steve Poirier, Gaetan Mayer, Suzanne Benjannet, Eric Bergeron, Jadwiga Marcinkiewicz, Nasha Nassoury, Harald Mayer, Johannes Nimpf, Annik Prat, Nabil G Seidah. J Biol Chem 2008
306
15

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Ahmed Zaid, Anna Roubtsova, Rachid Essalmani, Jadwiga Marcinkiewicz, Ann Chamberland, Josée Hamelin, Michel Tremblay, Hélène Jacques, Weijun Jin, Jean Davignon,[...]. Hepatology 2008
277
15

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.
Jonathan Cohen, Alexander Pertsemlidis, Ingrid K Kotowski, Randall Graham, Christine Kim Garcia, Helen H Hobbs. Nat Genet 2005
899
14

PCSK9 and inflammation: a review of experimental and clinical evidence.
Amir Abbas Momtazi-Borojeni, Sarvenaz Sabouri-Rad, Antonio M Gotto, Matteo Pirro, Maciej Banach, Zuhier Awan, George E Barreto, Amirhossein Sahebkar. Eur Heart J Cardiovasc Pharmacother 2019
47
29

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Paul M Ridker, Brendan M Everett, Tom Thuren, Jean G MacFadyen, William H Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D Anker,[...]. N Engl J Med 2017
13

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Stephen J Nicholls, Rishi Puri, Todd Anderson, Christie M Ballantyne, Leslie Cho, John J P Kastelein, Wolfgang Koenig, Ransi Somaratne, Helina Kassahun, Jingyuan Yang,[...]. JAMA 2016
515
13

Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in Apoptosis.
Zufeng Ding, Shijie Liu, Xianwei Wang, Pankaj Mathur, Yao Dai, Sue Theus, Xiaoyan Deng, Yubo Fan, Jawahar L Mehta. Antioxid Redox Signal 2016
37
35

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.
Karin Leander, Anders Mälarstig, Ferdinand M Van't Hooft, Craig Hyde, Mai-Lis Hellénius, Jason S Troutt, Robert J Konrad, John Öhrvik, Anders Hamsten, Ulf de Faire. Circulation 2016
119
13

PCSK9: a key modulator of cardiovascular health.
Nabil G Seidah, Zuhier Awan, Michel Chrétien, Majambu Mbikay. Circ Res 2014
359
13

Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2.
Hyun Jeong Jeong, Hyun-Sook Lee, Kyung-Sup Kim, Yoon-Kyoung Kim, Dojun Yoon, Sahng Wook Park. J Lipid Res 2008
238
13

NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.
Suzanne Benjannet, David Rhainds, Rachid Essalmani, Janice Mayne, Louise Wickham, Weijun Jin, Marie-Claude Asselin, Josée Hamelin, Mathilde Varret, Delphine Allard,[...]. J Biol Chem 2004
452
13

Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals.
Chiara Macchi, Nicola Ferri, Chiara Favero, Laura Cantone, Luisella Vigna, Angela C Pesatori, Maria G Lupo, Cesare R Sirtori, Alberto Corsini, Valentina Bollati,[...]. Eur J Prev Cardiol 2019
27
48

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.
Christine Landlinger, Marianne G Pouwer, Claudia Juno, José W A van der Hoorn, Elsbet J Pieterman, J Wouter Jukema, Guenther Staffler, Hans M G Princen, Gergana Galabova. Eur Heart J 2017
120
12

Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease.
Sha Li, Yuan-Lin Guo, Rui-Xia Xu, Yan Zhang, Cheng-Gang Zhu, Jing Sun, Ping Qing, Na-Qiong Wu, Li-Xin Jiang, Jian-Jun Li. Atherosclerosis 2014
73
16


PCSK9 inhibition and inflammation: A narrative review.
Massimiliano Ruscica, Lale Tokgözoğlu, Alberto Corsini, Cesare R Sirtori. Atherosclerosis 2019
44
27

Liver fat accumulation is associated with circulating PCSK9.
Massimiliano Ruscica, Nicola Ferri, Chiara Macchi, Marica Meroni, Claudia Lanti, Chiara Ricci, Marco Maggioni, Anna Ludovica Fracanzani, Sara Badiali, Silvia Fargion,[...]. Ann Med 2016
77
14

The biology and therapeutic targeting of the proprotein convertases.
Nabil G Seidah, Annik Prat. Nat Rev Drug Discov 2012
482
11


Inflammatory and Cholesterol Risk in the FOURIER Trial.
Erin A Bohula, Robert P Giugliano, Lawrence A Leiter, Subodh Verma, Jeong-Gun Park, Peter S Sever, Armando Lira Pineda, Narimon Honarpour, Huei Wang, Sabina A Murphy,[...]. Circulation 2018
121
11

Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.
Anna Roubtsova, Mercedes Nancy Munkonda, Zuhier Awan, Jadwiga Marcinkiewicz, Ann Chamberland, Claude Lazure, Katherine Cianflone, Nabil G Seidah, Annik Prat. Arterioscler Thromb Vasc Biol 2011
179
11

Prognostic value of PCSK9 levels in patients with acute coronary syndromes.
Baris Gencer, Fabrizio Montecucco, David Nanchen, Federico Carbone, Roland Klingenberg, Nicolas Vuilleumier, Soheila Aghlmandi, Dik Heg, Lorenz Räber, Reto Auer,[...]. Eur Heart J 2016
96
11

Cognitive Function in a Randomized Trial of Evolocumab.
Robert P Giugliano, François Mach, Kenton Zavitz, Christopher Kurtz, Kyungah Im, Estella Kanevsky, Jingjing Schneider, Huei Wang, Anthony Keech, Terje R Pedersen,[...]. N Engl J Med 2017
246
11

Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system.
Steve Poirier, Annik Prat, Edwige Marcinkiewicz, Joanne Paquin, Babykumari P Chitramuthu, David Baranowski, Benoit Cadieux, Hugh P J Bennett, Nabil G Seidah. J Neurochem 2006
78
14

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.
Da-Wei Zhang, Thomas A Lagace, Rita Garuti, Zhenze Zhao, Meghan McDonald, Jay D Horton, Jonathan C Cohen, Helen H Hobbs. J Biol Chem 2007
540
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.